These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24804542)

  • 1. TET1 exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer.
    Fu HL; Ma Y; Lu LG; Hou P; Li BJ; Jin WL; Cui DX
    J Biomed Nanotechnol; 2014 Jul; 10(7):1217-30. PubMed ID: 24804542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of TET1 facilitates DLD1 colon cancer cell migration via H3K27me3-mediated down-regulation of E-cadherin.
    Zhou Z; Zhang HS; Liu Y; Zhang ZG; Du GY; Li H; Yu XY; Huang YH
    J Cell Physiol; 2018 Feb; 233(2):1359-1369. PubMed ID: 28513825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TET1 inhibits gastric cancer growth and metastasis by PTEN demethylation and re-expression.
    Pei YF; Tao R; Li JF; Su LP; Yu BQ; Wu XY; Yan M; Gu QL; Zhu ZG; Liu BY
    Oncotarget; 2016 May; 7(21):31322-35. PubMed ID: 27121319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin in p53 mutant gastric cancer cells.
    Bai J; Ma M; Cai M; Xu F; Chen J; Wang G; Shuai X; Tao K
    Cell Prolif; 2014 Jun; 47(3):211-8. PubMed ID: 24738879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
    Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P
    J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease of 5hmC in gastric cancers is associated with TET1 silencing due to with DNA methylation and bivalent histone marks at TET1 CpG island 3'-shore.
    Park JL; Kim HJ; Seo EH; Kwon OH; Lim B; Kim M; Kim SY; Song KS; Kang GH; Kim HJ; Choi BY; Kim YS
    Oncotarget; 2015 Nov; 6(35):37647-62. PubMed ID: 26462176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.
    Choi JH; Song YS; Yoon JS; Song KW; Lee YY
    APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
    Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
    Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust quantitative assessments of cytosine modifications and changes in the expressions of related enzymes in gastric cancer.
    Du C; Kurabe N; Matsushima Y; Suzuki M; Kahyo T; Ohnishi I; Tanioka F; Tajima S; Goto M; Yamada H; Tao H; Shinmura K; Konno H; Sugimura H
    Gastric Cancer; 2015 Jul; 18(3):516-25. PubMed ID: 25098926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
    Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
    Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
    Pietersen AM; Horlings HM; Hauptmann M; Langerød A; Ajouaou A; Cornelissen-Steijger P; Wessels LF; Jonkers J; van de Vijver MJ; van Lohuizen M
    Breast Cancer Res; 2008; 10(6):R109. PubMed ID: 19099573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.
    Jie B; Weilong C; Ming C; Fei X; Xinghua L; Junhua C; Guobin W; Kaixiong T; Xiaoming S
    Int J Biochem Cell Biol; 2015 Aug; 65():104-12. PubMed ID: 26004298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
    Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
    Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.
    Matsukawa Y; Semba S; Kato H; Ito A; Yanagihara K; Yokozaki H
    Cancer Sci; 2006 Jun; 97(6):484-91. PubMed ID: 16734726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
    Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
    Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1.
    Liu C; Liu L; Chen X; Shen J; Shan J; Xu Y; Yang Z; Wu L; Xia F; Bie P; Cui Y; Bian XW; Qian C
    PLoS One; 2013; 8(5):e62828. PubMed ID: 23671639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated p53 suppresses the histone methyltransferase EZH2 gene.
    Tang X; Milyavsky M; Shats I; Erez N; Goldfinger N; Rotter V
    Oncogene; 2004 Jul; 23(34):5759-69. PubMed ID: 15208672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer.
    Mattioli E; Vogiatzi P; Sun A; Abbadessa G; Angeloni G; D'Ugo D; Trani D; Gaughan JP; Vecchio FM; Cevenini G; Persiani R; Giordano A; Claudio PP
    J Cell Physiol; 2007 Jan; 210(1):183-91. PubMed ID: 16998811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer.
    Chen DL; Zhang DS; Lu YX; Chen LZ; Zeng ZL; He MM; Wang FH; Li YH; Zhang HZ; Pelicano H; Zhang W; Xu RH
    Oncotarget; 2015 May; 6(13):10868-79. PubMed ID: 25869101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
    Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
    Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.